Clinical Trial Update: Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating targeted immunotherapy after myeloablative conditioning and allogeneic stem cell transplant in children and young adults with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Lymphoma

Snippet

Sponsor: New York Medical College | Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma | Phase 1 | Status: RECRUITING